23.5 C
New York
Thursday, July 3, 2025

Tag: acid

Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises

New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website 

NGEx Drills 46.8m at 9.55% CuEq plus 48.9m at 7.75% CuEq at Lunahuasi

VANCOUVER, BC, July 2, 2025 /CNW/ - NGEx Minerals Ltd. ("NGEx", "NGEx Minerals" or the "Company") (TSX: NGEX) (OTCQX: NGXXF) is pleased to announce additional...

ASHRAM PERFECTLY PLACED TO CAPITALISE ON CANADA’S PROMISE TO INCREASE SPENDING ON CRITICAL MINERALS

CANADIAN GOVERNMENT'S COMMITMENT TO MEET NATO SPENDING TARGET  BY DEVELOPING CRITICAL MINERALS COULD DELIVER MAJOR BENEFITS TO ASHRAM MONTREAL, July 2, 2025 /CNW/ -- Commerce...

FSI ANNOUNCES RECEIPT OF A $2.5 MILLION PAYMENT FOR ASSISTING IN THE DEVELOPMENT A NEW FOOD GRADE PRODUCT

TABER, ALBERTA, July 01, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. FSI is also increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces it has received payment of US$2.5million for assisting in developing a new food grade product.

EZGO ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED MARCH 31, 2025

CHANGZHOU, China, July 1, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions...

GlucoTru Pro Releases 2025 Health Integrity Update on Blood Pressure & Blood Sugar Balance Innovation

In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.

Effective Testosterone Booster for Men Over 50: TestoPrime Medically Accredited as the Best Testosterone Supplement for Males In 40’s and 50’s

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription
Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...

Ecovyst Issues 2024 Sustainability Report

WAYNE, Pa., June 30, 2025 /PRNewswire/ -- Ecovyst Inc. (NYSE: ECVT), a leading integrated and innovative global provider of advanced materials, specialty catalysts, virgin...

Olin and K2 Announce Strategic Expansion of Bleach Distribution Partnership in California and the Western United States

CLAYTON, Mo., June 30, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) and K2 Pure Solutions are pleased to announce an expansion of their strategic partnership...

Arizona Metals Announces 2025 Mineral Resource Estimate for Kay Mine Project

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR...

Java Brain Releases 2025 Research Update on Coffee-Based Neuroinflammation Trends and Cognitive Wellness Support

The 2025 update explores how evolving consumer interest in brain fog, coffee-enhanced wellness routines, and ingredient transparency is shaping the future of cognitive support.
The 2025 update explores how evolving consumer interest in brain fog, coffee-enhanced wellness routines, and ingredient transparency is shaping the future of cognitive support.

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Olin Corporation Second Quarter 2025 Earnings Conference Call Announcement

CLAYTON, Mo., June 26, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Tuesday, July 29, 2025, at 9:00 a.m. Eastern time, Olin's...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAcid